The quarter showcased SRF's operational prowess with net sales reaching an all-time high of ₹5,033.26 crores, up 9.06% QoQ and 31.81% YoY. Operating margins expanded significantly to 25.04%, marking the highest level in recent quarters and reflecting improved product mix, operating leverage, and cost management initiatives. However, the company's elevated valuation multiples—trading at 44 times trailing twelve-month earnings—continue to weigh on investor sentiment despite the strong fundamental performance.
| Quarter | Net Sales (₹ Cr) | Net Profit (₹ Cr) | Operating Margin | PAT Margin |
|---|---|---|---|---|
| Jun'26 | 5,033.26 (▲9.06%) | 758.87 (▲30.39%) | 25.04% | 15.36% |
| Mar'26 | 4,615.17 (▲24.31%) | 582.02 (▲34.52%) | 22.63% | 12.84% |
| Dec'25 | 3,712.53 (▲1.99%) | 432.66 (▲11.46%) | 21.60% | 11.98% |
| Sep'25 | 3,640.19 (▼4.67%) | 388.18 (▼10.21%) | 21.90% | 10.98% |
| Jun'25 | 3,818.62 (▼11.47%) | 432.32 (▼17.82%) | 22.20% | 11.56% |
| Mar'25 | 4,313.34 (▲23.55%) | 526.06 (▲94.06%) | 22.71% | 12.48% |
| Dec'24 | 3,491.31 | 271.08 | 18.19% | 7.96% |
Financial Performance: Margin Expansion Drives Profitability Surge
SRF's Q1 FY27 results demonstrated exceptional operational execution, with net sales climbing to a record ₹5,033.26 crores from ₹4,615.17 crores in the previous quarter. The 9.06% sequential growth was accompanied by impressive margin expansion, as operating profit (PBDIT excluding other income) surged to ₹1,236.72 crores, representing a margin of 25.04%—the highest in at least seven quarters. This 241 basis point QoQ improvement in operating margins reflected favourable product mix shifts, improved capacity utilisation, and effective cost management across raw materials and logistics.
The profitability trajectory was equally compelling. Profit before tax reached ₹979.15 crores in Q1 FY27, marking a 29.33% QoQ increase and a 70.06% YoY surge. The company's effective tax rate moderated to 22.50% from 23.13% in the previous quarter, contributing to the strong net profit performance. PAT margins expanded to 15.36% from 12.84% in Q4 FY26, underscoring the quality of earnings and operational leverage inherent in the business model.
Interest costs increased to ₹68.62 crores from ₹61.96 crores QoQ, reflecting higher working capital requirements to support robust revenue growth. However, the operating profit to interest coverage ratio remained healthy at 18.02 times, well above comfort levels and indicating strong debt servicing capability. Depreciation charges remained relatively stable at ₹222.86 crores, reflecting the capital-intensive nature of the speciality chemicals business.
Operational Excellence: Capital Efficiency and Balance Sheet Strength
SRF's operational metrics reveal a company operating at peak efficiency. The Return on Equity (ROE) of 15.63% places the company in the "good" category for capital efficiency, demonstrating management's ability to generate attractive returns on shareholder capital. This is particularly noteworthy given the capital-intensive nature of the speciality chemicals sector, where maintaining double-digit ROE consistently requires operational discipline and strategic pricing power.
The company's balance sheet as of March 2026 reflected robust fundamentals with shareholder funds of ₹14,042.76 crores, up from ₹12,626.20 crores in the previous year. Long-term debt stood at ₹1,953.30 crores, resulting in a comfortable net debt to equity ratio of 0.28—well below the industry average and providing ample financial flexibility for growth investments. The debt to EBITDA ratio of 1.52 times indicates strong debt servicing capability and conservative leverage.
Fixed assets totalled ₹13,683.58 crores, reflecting ongoing capacity expansion initiatives across SRF's diversified business portfolio. Current assets of ₹7,197.61 crores provided adequate liquidity to support operations, with cash and cash equivalents reaching a high of ₹610.96 crores. The company's working capital management showed some pressure with the debtors turnover ratio declining, suggesting extended collection cycles—a metric worth monitoring in coming quarters.
Key Operational Highlights
Operating Cash Flow Strength: Annual operating cash flow reached ₹2,345.55 crores, the highest on record, demonstrating strong cash generation capabilities. The company's cash flow from operations of ₹2,553 crores in FY26 comfortably exceeded capital expenditure requirements, enabling self-funded growth while maintaining shareholder distributions.
Capital Efficiency: Return on Capital Employed (ROCE) of 16.86% on average and 14.25% in the latest period reflects efficient asset utilisation and competitive advantages in the speciality chemicals space. The company's sales to capital employed ratio of 0.91 times indicates healthy asset turnover.
Industry Context: Navigating Speciality Chemicals Headwinds
The speciality chemicals sector has faced a challenging environment over the past year, with oversupply conditions in certain segments, Chinese competition, and demand moderation in key end-markets impacting industry profitability. Against this backdrop, SRF's ability to deliver 31.81% YoY revenue growth and significant margin expansion demonstrates the company's differentiated positioning and execution capabilities.
SRF's diversified business model spanning chemicals, technical textiles, packaging films, and fluorochemicals provides natural hedges against sector-specific headwinds. The company's leadership position in refrigerant gases, agrochemicals intermediates, and industrial yarns enables pricing power and customer stickiness that smaller competitors struggle to replicate. Management's focus on value-added speciality products rather than commoditised offerings has supported margin resilience even as volume growth has moderated.
However, the sector remains vulnerable to raw material price volatility, regulatory changes (particularly around fluorochemicals and environmental compliance), and global demand cycles. The company's international operations across India, Thailand, South Africa, and Hungary provide geographic diversification but also expose it to currency fluctuations and geopolitical risks.
| Company | P/E Ratio (TTM) | P/BV Ratio | ROE (%) | Debt to Equity | Dividend Yield |
|---|---|---|---|---|---|
| SRF | 44.49 | 6.06 | 15.63% | 0.28 | 0.31% |
| Pidilite Industries | 66.58 | 15.12 | 20.37% | -0.35 | 0.93% |
| Gujarat Fluorochemicals | 86.18 | 6.48 | 12.99% | 0.22 | 0.07% |
| Himadri Speciality | 48.48 | 8.23 | 11.70% | -0.02 | 0.10% |
| Navin Fluorine Intl. | 59.73 | 10.06 | 13.77% | -0.01 | 0.19% |
| Deepak Nitrite | 41.26 | 3.96 | 18.20% | 0.20 | 0.44% |
Within the speciality chemicals peer group, SRF trades at a P/E multiple of 44.49 times—below the peer average of approximately 60 times but still at a significant premium to historical valuations. The company's ROE of 15.63% positions it favourably against most peers, though it trails Pidilite Industries (20.37%) and Deepak Nitrite (18.20%). SRF's Price-to-Book ratio of 6.06 times is moderate compared to peers like Pidilite (15.12x) and Navin Fluorine (10.06x), reflecting a more reasonable valuation on book value terms.
The company's debt to equity ratio of 0.28 is conservative, providing financial flexibility that many peers lack. However, SRF's dividend yield of 0.31% is among the lowest in the peer group, with a payout ratio of just 17.12%, suggesting management's preference for reinvesting cash flows into growth initiatives rather than returning capital to shareholders.
Valuation Analysis: Premium Multiples Test Investor Patience
SRF's valuation remains the primary point of contention for investors. Trading at 44.49 times trailing twelve-month earnings, the stock commands a substantial premium to its long-term historical average and significantly exceeds broader market multiples. The Price-to-Book ratio of 6.06 times, while lower than some consumer-facing peers, still reflects elevated expectations embedded in the current share price of ₹2,873.10.
The company's EV/EBITDA multiple of 26.12 times and EV/EBIT of 34.83 times suggest the market is pricing in continued margin expansion and strong earnings growth. However, with 5-year EBIT growth at 8.61%—modest by speciality chemicals standards—the valuation appears stretched. The PEG ratio of 0.84 suggests the stock isn't egregiously overvalued relative to growth, but offers limited margin of safety.
The stock's classification as "VERY EXPENSIVE" by quantitative valuation models reflects these concerns. Since transitioning to "Very Expensive" territory in November 2019, the stock has oscillated between valuation grades, currently firmly in expensive territory. At current levels, the stock is trading 11.81% below its 52-week high of ₹3,257.95 but remains 24.18% above its 52-week low of ₹2,313.75.
Shareholding Pattern: Institutional Reshuffling Continues
The shareholding pattern in Q1 FY27 revealed interesting institutional dynamics. Promoter holding remained rock-solid at 50.26%, with no pledging—a positive indicator of management confidence and alignment with minority shareholders. The Kama Holdings Limited, the primary promoter entity, holds 50.21% of the equity, with individual promoters holding marginal stakes.
Foreign Institutional Investors (FIIs) reduced their stake to 15.45% from 16.66% in the previous quarter, marking a 1.21 percentage point decline. This represented the fourth consecutive quarter of FII selling, with cumulative reduction of 2.78 percentage points since June 2025. The FII exodus suggests concerns about valuation and potentially better opportunities elsewhere in global emerging markets.
Conversely, Mutual Funds increased their holdings to 13.47% from 12.33%, adding 1.14 percentage points during the quarter. This marked the fourth consecutive quarter of MF accumulation, with total additions of 3.11 percentage points over this period. The domestic institutional buying provides a counterbalance to FII selling and reflects confidence in SRF's long-term prospects among Indian fund managers.
| Investor Category | Jun'26 | Mar'26 | Dec'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 50.26% | 50.26% | 50.26% | 0.00% |
| FII | 15.45% | 16.66% | 17.48% | -1.21% |
| Mutual Funds | 13.47% | 12.33% | 11.67% | +1.14% |
| Insurance | 7.37% | 7.00% | 6.89% | +0.37% |
| Other DII | 1.64% | 1.88% | 1.66% | -0.24% |
| Non-Institutional | 11.82% | 11.87% | 12.04% | -0.05% |
Insurance companies also increased exposure, raising their stake to 7.37% from 7.00%, adding 0.37 percentage points. Combined institutional holdings (FII + MF + Insurance + Other DII) stood at 37.92%, indicating strong institutional participation despite the recent FII selling. The presence of 498 FIIs and 35 mutual funds in the shareholder base reflects broad-based institutional interest.
Stock Performance: Underperformance Amid Sector Headwinds
SRF's stock performance over the past year has been disappointing, declining 8.68% compared to the Sensex's 6.61% fall, resulting in negative alpha of 2.07 percentage points. The underperformance is more pronounced when compared to the Speciality Chemicals sector, which delivered positive returns of 7.39% over the same period—a relative underperformance of 16.07 percentage points that raises questions about SRF-specific challenges versus broader sector trends.
However, the medium to long-term picture is more encouraging. Over three years, SRF has delivered returns of 29.77% compared to the Sensex's 15.10%, generating alpha of 14.67 percentage points. The five-year performance is particularly impressive, with the stock returning 81.73% versus the Sensex's 45.27%, translating to 36.46 percentage points of alpha. The ten-year return of 933.68% demonstrates the wealth-creating potential of quality speciality chemicals franchises over extended holding periods.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | 3.54% | -0.56% | +4.10% |
| 1 Month | 5.63% | -0.44% | +6.07% |
| 3 Months | 15.24% | -2.24% | +17.48% |
| 6 Months | 5.08% | -6.75% | +11.83% |
| YTD | -6.55% | -9.93% | +3.38% |
| 1 Year | -8.68% | -6.61% | -2.07% |
| 3 Years | 29.77% | 15.10% | +14.67% |
| 5 Years | 81.73% | 45.27% | +36.46% |
The stock's beta of 1.16 indicates higher volatility than the broader market, with annualised volatility of 29.04% over the past year—more than double the Sensex's 13.53%. This elevated volatility reflects the cyclical nature of the chemicals business and sensitivity to global demand cycles, raw material prices, and currency movements. The stock currently trades above all major moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), suggesting technical strength despite the recent pullback.
Investment Thesis: Quality Franchise Meets Valuation Headwinds
SRF presents a classic investment dilemma—a high-quality business with strong operational metrics trading at premium valuations that limit near-term upside potential. The company's Mojo score of 60/100 places it firmly in "HOLD" territory, reflecting the tension between fundamental strengths and valuation concerns.
The investment case rests on several pillars. First, SRF's diversified business model across chemicals, technical textiles, packaging films, and fluorochemicals provides earnings resilience and multiple growth avenues. Second, the company's market leadership positions in refrigerant gases, agrochemical intermediates, and industrial yarns confer pricing power and competitive moats. Third, strong cash generation (operating cash flow of ₹2,345.55 crores annually) and conservative leverage (net debt to equity of 0.28) provide financial flexibility for growth investments and shareholder returns.
However, several factors warrant caution. The 5-year EBIT growth rate of 8.61% is modest and doesn't justify the current 44.49x P/E multiple. The company's exposure to cyclical end-markets, regulatory risks (particularly around fluorochemicals), and Chinese competition in certain segments creates earnings volatility. The declining debtors turnover ratio suggests potential working capital pressures that bear monitoring.
Key Strengths & Risk Factors
✅ KEY STRENGTHS
- Exceptional Margin Expansion: Operating margins reached 25.04% in Q1 FY27, the highest in recent quarters, demonstrating pricing power and operational leverage.
- Strong Cash Generation: Operating cash flow of ₹2,345.55 crores annually with consistent conversion, enabling self-funded growth.
- Superior Capital Efficiency: ROE of 15.63% and ROCE of 16.86% reflect effective capital allocation and competitive advantages.
- Conservative Balance Sheet: Net debt to equity of 0.28 and debt to EBITDA of 1.52x provide financial flexibility.
- Diversified Business Model: Multiple revenue streams across chemicals, textiles, and packaging reduce concentration risk.
- Market Leadership: Dominant positions in refrigerant gases, agrochemical intermediates, and industrial yarns.
- Strong Institutional Support: 37.92% institutional holdings with increasing mutual fund participation.
⚠️ KEY CONCERNS
- Premium Valuation: Trading at 44.49x P/E with "Very Expensive" classification limits upside potential and increases downside risk.
- Modest EBIT Growth: 5-year EBIT CAGR of 8.61% doesn't justify elevated multiples and suggests limited pricing power in some segments.
- FII Selling Pressure: Four consecutive quarters of FII stake reduction totalling 2.78 percentage points signals institutional concerns.
- Sector Underperformance: Stock declined 8.68% over one year while sector gained 7.39%—a 16.07 percentage point underperformance.
- Working Capital Deterioration: Declining debtors turnover ratio suggests collection challenges or extended payment terms.
- Cyclical Exposure: Significant exposure to cyclical end-markets creates earnings volatility and limits visibility.
- Low Dividend Yield: 0.31% yield with 17.12% payout ratio offers minimal income for investors.
Outlook: What to Watch in Coming Quarters
POSITIVE CATALYSTS
- Sustained Margin Expansion: Ability to maintain 25%+ operating margins through product mix improvements and operating leverage.
- Volume Growth Acceleration: Recovery in global demand for speciality chemicals driving top-line momentum.
- Capacity Utilisation Improvement: Better asset sweating from recent capex delivering incremental profitability.
- Working Capital Normalisation: Improvement in debtors turnover indicating better cash conversion.
- Valuation Compression: Earnings growth outpacing stock price, bringing multiples to reasonable levels.
RED FLAGS TO MONITOR
- Margin Pressure: Operating margins reverting to 21-22% range due to competitive intensity or raw material inflation.
- Revenue Growth Deceleration: QoQ revenue growth falling below 5% indicating demand softness.
- Continued FII Exodus: Further institutional selling pressure driving valuation de-rating.
- Working Capital Deterioration: Further decline in debtors turnover or inventory buildup stressing cash flows.
- EBIT Growth Disappointment: Full-year EBIT growth remaining in single digits, failing to justify premium valuations.
The Verdict: Quality at a Price—Hold for Now
Score: 60/100
For Fresh Investors: Avoid fresh purchases at current valuations. SRF is a high-quality franchise, but the 44.49x P/E multiple and "Very Expensive" classification offer limited margin of safety. Wait for a meaningful correction towards ₹2,400-₹2,500 levels (providing 15-20% downside buffer) before initiating positions. The stellar Q1 performance is encouraging but already priced into current levels.
For Existing Holders: Continue holding with a long-term perspective. The company's strong fundamentals—15.63% ROE, robust cash generation, conservative balance sheet, and market leadership—support the investment thesis. However, consider booking partial profits if the stock rallies towards ₹3,100-₹3,200 levels. Maintain stop-loss discipline and reassess if operating margins compress or revenue growth decelerates materially.
Fair Value Estimate: ₹2,600 (9.5% downside from current levels). This valuation assumes 38x P/E on FY27 estimated earnings—still premium but more reasonable than current multiples. Meaningful upside requires either significant earnings upgrades or multiple expansion, both of which appear challenging in the near term given elevated starting valuations and modest historical EBIT growth.
Rationale: SRF's Q1 FY27 results validate its operational excellence with record revenues, impressive margin expansion to 25.04%, and 75.53% YoY profit growth. The company's quality credentials—good ROE, strong cash generation, conservative leverage, and market leadership—remain intact. However, valuation remains the Achilles' heel. At 44.49x trailing earnings and classified as "Very Expensive," the stock offers limited upside and significant downside risk if growth disappoints or multiples compress. The four consecutive quarters of FII selling and 16.07 percentage point underperformance versus the sector over one year suggest institutional investors share these valuation concerns. A HOLD rating reflects respect for the quality franchise while acknowledging valuation constraints that limit near-term return potential.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The views expressed are based on data available as of July 22, 2026, and are subject to change based on market conditions and company developments.
